The US$60 billion tax increase list will take effect next week | A variety of pharmaceutical products are listed

Pharmaceutical Network September 20, yesterday, the United States announced next Monday to impose tariffs on China's 200 billion goods, the Chinese Ministry of Commerce issued three statements and announcements on the same day, said that they will have to synchronize counter-measures, the Ministry of Finance official website will immediately issue the "State Council tariffs The Notice of the Taxation Commission on the application of tariffs on imports of approximately US$60 billion from the United States, that is, the relevant list in the previously issued [2018] No. 6 announcement, from 12:01 on September 24, 2018. About 60 billion goods are subject to a 5% or 10% tariff.

It is worth noting that the Chinese counter-production list is consistent with the previously published content, there are no new additions and deletions, but the tax rate has been generally lowered in actual implementation.

The tax rates previously drafted are: 25% tariffs on 2,493 items of tax items listed in List 1 of the US and Canada, and 20% tariffs on 1078 items of goods listed in Listing 2, 974 listed in Listing 3. Tax items are subject to a 10% tariff, and 662 tariff items listed in Listing 4 are subject to a 5% tariff.

According to the counter-product list of the US$60 billion that was finalized by the Chinese side, the four tariffs are divided into two categories, 5% and 10%, of which 3,571 tariff items are added to 10% of the tariff items, plus 5 % of tariff goods have 1,636 tax items.

The reporter of the "Medical Economics News" first sorted out the matter. The State Council's Customs Tariff Commission decided to include more types of pharmaceutical products in the goods that were subject to tariffs on the 5,207 tax items originating in the United States.

Involved with unmixed vitamin B2 and its derivatives; unmixed D or DL-pantothenic acid and its derivatives; unmixed vitamin B12 and its derivatives; recombinant human insulin and its salts; other insulins and their salts; other peptide hormones , protein hormones, glycoprotein hormones and their derivatives and similar structures; halogenated derivatives of other corticosteroids; halogenated derivatives of other corticosteroids; other steroid hormones and their derivatives and similar structures; Prostaglandins, thromboxanes and leukotrienes and their derivatives and structural analogues; other natural or synthetically prepared glycosides and their salts, ethers, esters and other derivatives; gentamicin and its derivatives and salts; Cephalosporins and their derivatives and their salts; adhesive plasters (drug-coated or retail packaging for medical, surgical, dental or veterinary use); X-ray contrast agents; diagnostic reagents; Chemical contraceptives, etc.

In addition, there are medical or laboratory disinfection equipment, acetaminophen (paracetamol), unmixed vitamin B6 and its derivatives, unmixed vitamin C and its derivatives.

Contains fresh, cold, frozen or dried American ginseng, first aid kit, medicine pack, gel product for human or veterinary use, as a lubricant for body parts during surgery or physical examination, or as a body and medical device Coupling agents, vulcanized rubber clothing and accessories for medical use, other sanitary and medical products made of vulcanized rubber, vulcanized rubber clothing and accessories for medical use, other non-medical X-ray equipment, medical alpha, beta, gamma-ray equipment, other medical, surgical Or veterinary furniture and parts.

In addition, o-acetylsalicylic acid (aspirin); salicylic acid other esters and their salts; procaine; amphetamine, benzethamine, dextroamphetamine, ethenamine, fencan Faming, rifampicin, levofloxacin, mefenex, phentermine and their salts; alfentanil, anilidine, cyanamide, bromozin, difenofril, diphene Nodyl ester, dipyridone, fentanyl, ketomizate, methylphenidate, pentazin, pethidine, meperidine intermediate A, phencyclidine, phenylphenidine, piperazine Methanol, piperazine, propidium and trimethylpyridin and their salts; alprazolam, carbamazepine, etc. and their salts; Amiris, bromozolam, chlorthiazide, etc. and their Salt; other antibiotics; other natural or synthetically reconstituted hormones and their derivatives and structural analogues, including modified chain polypeptides mainly used as hormones; other ampicillin salts; streptomycin and its derivatives, and their salts Other adhesive dressings and articles with adhesive coating (medicated, surgical, dental or veterinary); cotton wool, gauze, bandages (drug coated or ; retail packaging for medical, surgical, dental or veterinary use; other medical soft fillers and similar articles (medicated, surgical, dental or veterinary); sterile surgical gut; Bacterial kelp, sterile adhesive tape, sterile absorbent hemostatic material, surgical or dental sterile anti-adhesive barrier material and similar sterile material blood type reagent.

The latest 200 billion Chinese products exported to the United States on September 17th has a total of 194 pages of tax collection, involving 6031 products, accounting for 38%-46% of China's total exports to the United States in 2017. The latest tariff list in the US Nearly 300 tariff lines have been removed from the original list, and some sub-categories under specific breakdowns have been removed from the list, including smart watches, Bluetooth devices and other specific consumer products, specific chemicals, textiles. , agricultural products, some safe and healthy products, as well as rubber, plastic gloves, hospital hygiene products, etc. The previously mentioned herbal ginseng, food and dietary supplement industry commonly used raw materials such as phospholipids are included.

According to the statistics of the Customs Department of the Ministry of Commerce, the raw materials for export to the United States in 2017, drug The scale of preparations and medical devices was 3.9 billion, 1.2 billion, and 5.8 billion US dollars, respectively accounting for 13%, 35%, and 27% of China's total exports of APIs, pharmaceutical preparations, and medical devices. Therefore, due to the small scale of exports to the United States, Chinese creature medicine The industry as a whole is limited by the Sino-US trade war.

According to the analysis of the Flint Institute, the United States has previously proposed special taxonomic drugs such as psychology and hormones in the proposed tax increase list. However, the current actual implementation of the tax increase list has removed the special drug substances. In addition, from the previous US tax increase list, A variety of biologic products were included in the first tariff list, but were eventually cancelled during implementation, such as human veterinary vaccines, blood products, insulin drugs, etc., and such products are exported to the United States in small quantities, so The Sino-US trade war has limited impact on the export of Chinese preparations and biological products.

Because the United States is China Healthy food The largest exporter, the export volume is twice that of the second Hong Kong, China. Moreover, some health food exports are re-exported to the United States through Hong Kong, China, etc., so the proportion of health food actually exported to the United States may be higher. If the United States implements a list to increase import tariffs on domestically produced varieties, it will have a certain impact on the export of Chinese health food.

However, it is worth noting that the Sino-US trade war will lead to high-end in China. medical instruments Exports are reduced, but in the short term, the overall impact on medical devices is small. In the long run, the trade war will affect the development of high-end medical devices in the global market to a certain extent.

Relevant enterprises can first check the Sino-US list. It is worth noting that the professionals reminded that the pharmaceutical companies that conduct product self-examination against the US list should pay attention to the customs code in the list, which is the US Customs code, and the customs code of the Chinese exporter. Not exactly the same, please check the top 6 and then confirm whether the product is included in the list according to the product description, and then confirm with the US customer.

In the face of the 'crisis' that may exist in the trade war, the industry suggests that pharmaceutical companies should meet the opportunity in danger.

An expert from the Economic Research Institute of the Chinese Academy of Social Sciences said in an interview with the media that the recent trade dispute can be understood as finding a new balanced solution for the market and moving forward in the adjustment. In its view, the Sino-US pharmaceutical market linkage Close, interactive exchanges, products, R&D projects, etc. all have cooperative relationships and are in a state of long-term mutual benefit. Both sides of the game can stimulate innovation and dynamic reshuffle in the dynamic adjustment.

However, in any case, pharmaceutical companies that have a relatively heavy export to the US should focus on risks. It is necessary to prepare the plan ahead of time to minimize the losses caused by this risk. At the same time, it is the core to enhance its own quality and innovation. In addition, domestic enterprises should expand In the Chinese market, domestic demand will increase the trade quotas of other countries and regions. For example, in terms of foreign trade, China actively expands its export business to other countries in Europe and Asia under the core strategy of “One Belt, One Road”.